We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

22 hedge funds and large institutions have $1.12M invested in Cardiff Oncology in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

0.29% less ownership

Funds ownership: 12.33% → 12.04% (-0.29%)

4% less funds holding

Funds holding: 23 → 22 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

33% less capital invested

Capital invested by funds: $1.68M → $1.12M (-$551K)

Holders
22
Holders Change
-1
Holders Change %
-4.35%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$118K
2
EP
Elkhorn Partners
Nebraska
+$33.1K
3
PFS
Prospera Financial Services
Texas
+$19.7K
4
WS
Wedbush Securities
California
+$6.81K
5
UBS Group
UBS Group
Switzerland
+$5.72K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$26K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$21.9K
3
Morgan Stanley
Morgan Stanley
New York
-$4K
4
JP Morgan Chase
JP Morgan Chase
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$468K +$118K +60,482 +24%
Vanguard Group
2
Vanguard Group
Pennsylvania
$414K -$21.9K -11,231 -4%
EP
3
Elkhorn Partners
Nebraska
$56K +$33.1K +17,000 +85%
Morgan Stanley
4
Morgan Stanley
New York
$38K -$4K -2,057 -8%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$31K – – –
ARTA
6
A.R.T. Advisors
New York
$28K +$3.47K +1,781 +11%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$25K – – –
WS
8
Wedbush Securities
California
$20K +$6.81K +3,500 +35%
PFS
9
Prospera Financial Services
Texas
$15K +$19.7K +10,117 New
UBS Group
10
UBS Group
Switzerland
$12K +$5.72K +2,939 +62%
BlackRock
11
BlackRock
New York
$8K – – –
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$4K – – –
PNC Financial Services Group
13
PNC Financial Services Group
Pennsylvania
$2K +$1.95K +1,000 New
Barclays
14
Barclays
United Kingdom
$1K – – –
CAPTRUST Financial Advisors
15
CAPTRUST Financial Advisors
North Carolina
$1K – – –
Victory Capital Management
16
Victory Capital Management
Texas
$1K +$1.75K +900 New
BNP Paribas Financial Markets
17
BNP Paribas Financial Markets
France
$2 – – –
TSS
18
Two Sigma Securities
New York
– -$26K -10,216 Closed
JP Morgan Chase
19
JP Morgan Chase
New York
– -$2K -846 Closed
Bank of America
20
Bank of America
North Carolina
– +$510 +262 +374%

CRDF Hedge Fund Activity: Q3 2019 in Review

22 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2019, worth a combined $1.12M — down 33% from $1.68M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CRDF and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $118K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $26K sold.

  • 22 institutional investors held Cardiff Oncology (CRDF) as of Q3 2019, down from 23 in Q2 2019.
  • Funds reported $1.12M of Cardiff Oncology stock for Q3 2019, down 33% quarter-over-quarter.
  • 3 funds opened new Cardiff Oncology positions in Q3 2019 and 4 closed out, a net change of -1 holder.
  • The largest Cardiff Oncology buyer in Q3 2019 was Renaissance Technologies, an estimated $118K added.
  • The largest Cardiff Oncology seller in Q3 2019 was Two Sigma Securities, an estimated $26K sold.

Based on aggregated 13F filings for Q3 2019.